

EFFICACY AND SAFETY OF INTERFERON ALPHA 2AIN THE TREATMENT OF LARYNGEAL PAPILLOMATOSIS: A CASE REPORT



M.I. SIERRA TORRES¹, C. ALAVREZ DEL VAYO BENITO¹,A. RODRIGUEZ PÉREZ¹,M.D. TOSCANO GUZMAN¹, A. GARCIA-AVELLO FERNANDEZ-CUETO¹, J. MARTINEZ TURRIÓN¹, C. VILLANUEVA BUENO¹ ¹HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO, PHARMACY, SEVILLE, Spain.

BACKGROUND

- > Laryngeal papillomatosis is a neoplasm of the larynx that is due to an infection by the human papillomavirus (HPV).
- It is characterized by tumors within the voice box, vocal cords or the air duct, causing breathing problems, dysphagia, stridor and sore throat.
- > The treatment of choice is surgery, but some patients require adjuvant treatment, such as cidofovir or alpha interferon.

PURPOSE

>To describe the efficacy and safety of the treatment with interferon alpha 2A in laryngeal papillomatosis.

MATERIAL AND METHOD

One-year female patient with laryngeal papillomatosis from perinatal transmission









RESULTS



First week 100.000UI/kg one doseNext weeks 3doses/week



BENEFITS

*No lesion progression *Disapearance os fome lesons *More time between consultations (1 to 2 months)



ADVERSE EVENTS

*Dominant face erythematous lesions *Fever

CONCLUSIONS

It seems that interferon alpha 2-A is an effective and relatively safe treatment, as described adverse effects have not been a great damage to the patient in the treatment of laryngeal papillomatosis. It is necessary to monitor the use of interferon alfa because it has been only used for 5 months in one patient, although the results are encouraging to be consider as a new therapeutic alternative to these patients.